These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38730737)

  • 21. Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors.
    Winograd P; Hou S; Court CM; Lee YT; Chen PJ; Zhu Y; Sadeghi S; Finn RS; Teng PC; Wang JJ; Zhang Z; Liu H; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
    Hepatol Commun; 2020 Oct; 4(10):1527-1540. PubMed ID: 33024921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.
    Singal AG; Özgürdal K; Fan X; Vassilev Z; Pan X; Multani JK; Chen CC; Zhou Z; He J; Pisa F
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y;
    J Gastroenterol Hepatol; 2023 Aug; 38(8):1389-1397. PubMed ID: 37231943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma.
    Chiang PJ; Xu T; Cha TL; Tsai YT; Liu SY; Wu ST; Meng E; Tsao CW; Kao CC; Chen CL; Sun GH; Yu DS; Chang SY; Yang MH
    Biology (Basel); 2021 Jul; 10(7):. PubMed ID: 34356529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
    Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
    Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.
    Matsumae T; Kodama T; Myojin Y; Maesaka K; Sakamori R; Takuwa A; Oku K; Motooka D; Sawai Y; Oshita M; Nakabori T; Ohkawa K; Miyazaki M; Tanaka S; Mita E; Tawara S; Yakushijin T; Nozaki Y; Hagiwara H; Tahata Y; Yamada R; Hikita H; Tatsumi T; Takehara T
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
    Kennedy LC; Lu J; Kuehn S; Ramirez AB; Lo E; Sun Y; U'Ren L; Chow LQM; Chen Z; Grivas P; Kaldjian EP; Gadi VK
    Target Oncol; 2022 May; 17(3):329-341. PubMed ID: 35696014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma.
    Su K; Guo L; He K; Rao M; Zhang J; Yang X; Huang W; Gu T; Xu K; Liu Y; Wang J; Chen J; Wu Z; Hu L; Zeng H; Li H; Tong J; Li X; Yang Y; Liu H; Xu Y; Tan Z; Tang X; Feng X; Chen S; Yang B; Jin H; Zhu L; Li B; Han Y
    Front Oncol; 2022; 12():873830. PubMed ID: 35982979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
    Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
    Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
    Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.
    Wang K; Xiang YJ; Yu HM; Cheng YQ; Liu ZH; Zhong JY; Feng S; Ni QZ; Zhu HF; Pan WW; Li JJ; Liang C; Zhou HK; Meng Y; Lau WY; Cheng SQ
    Front Immunol; 2023; 14():1107542. PubMed ID: 36875125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal.
    Kawamura Y; Akuta N; Fujiyama S; Suzuki F; Kumada H
    Cureus; 2023 Sep; 15(9):e45385. PubMed ID: 37854758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.
    Yu Q; Wang Y; Ungchusri E; Patel M; Kumari D; Van Ha T; Pillai A; Liao CY; Ahmed O
    J Interv Med; 2023 Nov; 6(4):187-193. PubMed ID: 38312131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Yamauchi Y; Saeki I; Yamasaki T; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Nishimura T; Tanabe N; Oono T; Matsumoto T; Ishikawa T; Marumoto Y; Matsukuma S; Shindo Y; Tokumitsu Y; Yoshimine S; Murakami J; Tanaka T; Kimura S; Hoshii Y; Hamano K; Nagano H; Takami T
    Hepatol Res; 2023 Jul; 53(7):681-686. PubMed ID: 36826420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
    Tanabe N; Saeki I; Aibe Y; Matsuda T; Hanazono T; Nishi M; Hidaka I; Kuwashiro S; Shiratsuki S; Matsuura K; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Sasaki R; Nishimura T; Oono T; Hisanaga T; Matsumoto T; Ishikawa T; Yamasaki T; Takami T
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
    Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
    Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
    Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
    Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.